Just FYI I bought more today at the close - got some more at $36 1/2. Will it go down more? Possibly. And I'll be there buying some more if it drops to $34.00. Also shorted Merck today at the close. Gotta friend that just left Merck and went to Schering Plough. He says Merck WILL NOT hit meet next quarter's estimate and that the pipeline is not looking good. Massive cuts are coming at Merck. He and his supervisor both bailed and went to SGP. Good luck with your MRK investment - you'll need it.
Looks like bartbj's friends are full of good information. Check out his post. The day before a HUGE run up he's posting tips that MRK future is grim. Easy to see you are ALONE in that thinking. Shorted Merck on the close? OUCH! That was dumb! What did you lose on that trade? Did your ABT make up for it? hahahaha Let this be a lesson to anyone who listens to Bartbj. His shorts go up and his longs go sideways.
So Bartbj, You bought 50 shares? 100 shares? Do tell. I've got a feelling you either bought very small or are frightened it will go down more at which point I'll say "hahaha" and you'll say "so what? I only bought 20 shares!"
Speaking of pipeline, latest out of just concluded San Francisco meetings indicated that ABT's new AIDS drug will have FDA sanction for early access program. That means physicians will get to use the drug on selected patients prior to full FDA approval. A good start for the most potent drug of this class. Also, a new antibiotic in final clinical trials was effective against respiratory bacteria resistant to macrolides such as Biaxin (ABT) and Zithromax (PFE). This drug would compete favorably with Zithromax (i.e. single dosage, short treatment and broad spectrum). Finally, there is still life for Biaxin which was competing for narrow spectrum with quinolines such as PFE's Trovan. Recent problems with toxicity of Trovan and quinolines in general makeing fallback to safer macrolides appealing. Digest those facts.